Published in Arthritis Res Ther on April 26, 2012
Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'. Arthritis Res Ther (2013) 0.91
Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism. J Bone Miner Res (2015) 0.84
Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis. Arthritis Res Ther (2014) 0.81
Novel applications of statins for bone regeneration. Natl Sci Rev (2014) 0.77
Statin use and markers of immunity in the Doetinchem cohort study. PLoS One (2013) 0.76
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply. Arthritis Res Ther (2013) 0.75
Statins: a revised appraisal for potential additional future treatment indications. Arthritis Res Ther (2012) 0.75
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 4.58
Current perspectives on statins. Circulation (2000) 3.83
Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol (2007) 3.36
Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol (1997) 3.35
IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol (2001) 3.32
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum (1996) 2.92
A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest (1999) 2.65
High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol (1997) 2.59
Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 2.49
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol (1988) 1.85
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis (2007) 1.81
Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact (2001) 1.79
Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol (2001) 1.50
Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol (2000) 1.45
Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum (2011) 1.43
Dose-response modeling of continuous endpoints. Toxicol Sci (2002) 1.28
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis (2011) 1.20
Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev (2003) 1.12
Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis (2011) 1.10
Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum (2004) 1.09
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol (2006) 1.06
Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-γ. J Interferon Cytokine Res (2011) 1.01
Collagen-induced arthritis in mice. Methods Mol Biol (2010) 0.94
Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int (2006) 0.90
Rodent models of rheumatoid arthritis. Comp Med (2005) 0.89
Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus (2012) 0.87
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity (2006) 0.80
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Instrumental variables: application and limitations. Epidemiology (2006) 3.03
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
A retrospective analysis of the two-generation study: what is the added value of the second generation? Reprod Toxicol (2007) 2.24
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens (2009) 2.14
Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med (2007) 2.09
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J (2010) 2.00
Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol (2011) 1.94
Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med (2002) 1.73
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J (2012) 1.67
Endocrine effects of tetrabromobisphenol-A (TBBPA) in Wistar rats as tested in a one-generation reproduction study and a subacute toxicity study. Toxicology (2007) 1.63
Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens (2005) 1.58
Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens (2009) 1.50
Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost (2008) 1.48
A 28-day oral dose toxicity study in Wistar rats enhanced to detect endocrine effects of decabromodiphenyl ether (decaBDE). Toxicol Lett (2008) 1.48
Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother (2005) 1.47
Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts. Stroke (2008) 1.45
Sub-chronic toxicity study in rats orally exposed to nanostructured silica. Part Fibre Toxicol (2014) 1.44
Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum (2011) 1.43
Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis (2004) 1.43
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACS Nano (2012) 1.34
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med (2008) 1.30
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis (2011) 1.27
Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother (2005) 1.23
Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res (2009) 1.16
Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol (2012) 1.16
Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS One (2010) 1.11
Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf (2005) 1.09
A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats. Toxicol Sci (2006) 1.07
Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf (2009) 1.07
Risk assessment of deoxynivalenol in food: concentration limits, exposure and effects. Adv Exp Med Biol (2002) 1.04
The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens (2004) 1.03
Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol (2005) 1.03
A 28-day oral dose toxicity study enhanced to detect endocrine effects of a purified technical pentabromodiphenyl ether (pentaBDE) mixture in Wistar rats. Toxicology (2007) 1.02
Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol (2008) 1.01
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J (2006) 1.01
Measuring balance and model selection in propensity score methods. Pharmacoepidemiol Drug Saf (2011) 0.99
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol (2008) 0.99
The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin (2008) 0.99
Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials (2013) 0.98
Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. Int J Food Microbiol (2006) 0.98
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics (2012) 0.97
Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol (2005) 0.96
Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol (2007) 0.95
Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol (2002) 0.95
Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf (2014) 0.95
An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol (2012) 0.95
Copper and human health: biochemistry, genetics, and strategies for modeling dose-response relationships. J Toxicol Environ Health B Crit Rev (2007) 0.95
Functional foods: the case for closer evaluation. BMJ (2007) 0.93
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics (2014) 0.93
Integration of probabilistic exposure assessment and probabilistic hazard characterization. Risk Anal (2007) 0.93
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics (2010) 0.92
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost (2010) 0.92
Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One (2012) 0.92
Propensity score balance measures in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf (2014) 0.91
A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens (2008) 0.91
Functional foods and dietary supplements: products at the interface between pharma and nutrition. Eur J Pharmacol (2011) 0.91
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics (2010) 0.91
Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci (2008) 0.91
Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiol Drug Saf (2011) 0.91
Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharm World Sci (2003) 0.90
Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol (2003) 0.90
Risk assessment of botanicals and botanical preparations intended for use in food and food supplements: emerging issues. Toxicol Lett (2008) 0.90
A comparison of three methods for calculating confidence intervals for the benchmark dose. Risk Anal (2004) 0.90
Should non-inferiority drug trials be banned altogether? Drug Discov Today (2013) 0.90
Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease. Stroke (2010) 0.89
Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. Br J Clin Pharmacol (2004) 0.89
Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Crit Rev Toxicol (2007) 0.89
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics (2005) 0.89
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet (2007) 0.89
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis (2002) 0.89
A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Ann Pharmacother (2010) 0.89
Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). Br J Clin Pharmacol (2006) 0.88
Contact and respiratory sensitizers can be identified by cytokine profiles following inhalation exposure. Toxicology (2009) 0.87
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens (2005) 0.87
Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem Toxicol (2010) 0.87
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs (2004) 0.86
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2004) 0.85
Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf (2003) 0.85
Should rosuvastatin be withdrawn from the market? Lancet (2004) 0.85
Endocrine effects of hexabromocyclododecane (HBCD) in a one-generation reproduction study in Wistar rats. Toxicol Lett (2008) 0.85
Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol (2011) 0.85
Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. J Clin Endocrinol Metab (2007) 0.84
Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. Pharmacoepidemiol Drug Saf (2013) 0.84
Genetic determinants of response to statins. Expert Rev Cardiovasc Ther (2009) 0.84
Ultraviolet radiation, resistance to infectious diseases, and vaccination responses. Methods (2002) 0.84
Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One (2012) 0.84
Can carcinogenic potency be predicted from in vivo genotoxicity data?: a meta-analysis of historical data. Environ Mol Mutagen (2011) 0.84
An exposure-response curve for copper excess and deficiency. J Toxicol Environ Health B Crit Rev (2010) 0.84
Propensity score methods and unobserved covariate imbalance: comments on "squeezing the balloon". Health Serv Res (2014) 0.83
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
A comparison of ratio distributions based on the NOAEL and the benchmark approach for subchronic-to-chronic extrapolation. Toxicol Sci (2005) 0.83
Developmental immunotoxicity of methylmercury: the relative sensitivity of developmental and immune parameters. Toxicol Sci (2010) 0.83
Instrumental variables in influenza vaccination studies: mission impossible?! Value Health (2009) 0.83